Home/Chronic Disease/Depression & Anxiety
🧠
Mental Health

Depression & Anxiety

Mental Health is Health — Evidence-Based Care in Primary Care

Understanding Depression & Anxiety

Depression and anxiety are the most prevalent mental health conditions worldwide. Major depressive disorder affects 1 in 6 Americans at some point in their lives; anxiety disorders affect 40 million adults in the US. Both conditions significantly impair quality of life, relationships, work productivity, and physical health. They are also highly comorbid — up to 60% of people with depression also have anxiety. Primary care is the most common setting in which mental health conditions are first identified and treated.

Signs & Symptoms

  • Depression: persistent sadness, hopelessness, loss of interest, fatigue, sleep changes, concentration problems
  • Anxiety: excessive worry, restlessness, irritability, muscle tension, sleep problems, panic attacks
  • Both: reduced social engagement, physical complaints (headaches, GI issues), difficulty at work or school
  • Suicidal thoughts — seek immediate care

Our Management Approach

We screen all patients for depression and anxiety as part of routine primary care. When identified, we discuss all treatment options — therapy, medication, lifestyle modification, and integrative approaches. We initiate treatment when appropriate, monitor response, adjust medications, and coordinate with mental health professionals for complex cases or therapy referral.

1
Validated Screening
PHQ-9 for depression, GAD-7 for anxiety — evidence-based tools to identify and track severity.
2
Medication Management
SSRIs and SNRIs are first-line for both depression and anxiety. We initiate, titrate, and monitor response carefully.
3
Therapy Referral
Cognitive behavioral therapy (CBT) is as effective as medication for many patients — we facilitate referrals to licensed therapists.
4
Lifestyle as Medicine
Exercise, sleep hygiene, social connection, and nutrition are powerful evidence-based interventions for both conditions.
5
Safety Assessment
Routine screening for suicidal ideation with a clear safety plan for at-risk patients.

Treatment Goals

  • PHQ-9 score below 5 (remission) from baseline
  • Restored ability to work, socialize, and function daily
  • Improved sleep quality
  • Reduced anxiety severity and panic frequency
  • Safe and well-tolerated medication regimen

Lifestyle Recommendations

  • •Exercise: 30 minutes of aerobic activity most days — as effective as antidepressants for mild-moderate depression
  • •Sleep: consistent 7–9 hours, address insomnia as its own condition
  • •Social connection: isolation worsens both depression and anxiety
  • •Reduce alcohol and caffeine — both worsen anxiety and depression
  • •Mindfulness and meditation: evidence-based for anxiety reduction
  • •Sunlight exposure: especially for seasonal affective disorder
  • •Limit social media and news exposure if these worsen anxiety

Medications & Treatment Options

  • 💊First-line SSRIs: sertraline (Zoloft) 50–200 mg, escitalopram (Lexapro) 10–20 mg, paroxetine (Paxil) 20–50 mg — excellent for both depression and anxiety
  • 💊SNRIs: venlafaxine (Effexor) 75–375 mg, duloxetine (Cymbalta) 40–60 mg — effective for both, plus pain relief benefit
  • 💊Augmentation: bupropion (Wellbutrin) 300 mg XL added to SSRI for depression not responsive to SSRI alone, improves motivation/energy
  • 💊Atypical anxiolytics: buspirone (Buspar) 15–60 mg for anxiety (non-controlled, lower abuse potential than benzodiazepines)
  • 💊Benzodiazepines: lorazepam (Ativan), alprazolam (Xanax) — short-term acute anxiety only; tapered within 2–4 weeks due to dependence/tolerance risk

Monitoring Schedule

Baseline: PHQ-9 and GAD-7 screening (all primary care patients); assess every 2–4 weeks initially after starting medication, then monthly × 3 months, then every 3 months; screen for suicidality at each visit

Clinical Protocol

Screen all patients with PHQ-9 and GAD-7 annually. PHQ-9 ≥10: mild depression; ≥15: moderate; ≥20: severe. GAD-7 ≥10: mild anxiety; ≥15: moderate; ≥20: severe. Mild symptoms: counsel lifestyle first (exercise, sleep, social support) × 2–4 weeks, then reassess. Moderate-severe or functional impairment: start SSRI immediately. Typical initiation: sertraline 50 mg or escitalopram 10 mg daily, increase every 1–2 weeks as tolerated to effect (usually 2–4 weeks). If no response after 4–6 weeks at therapeutic dose, switch SSRI, add bupropion, or refer to psychiatry. Refer to therapy (CBT proven effective): anxiety: CBT equals or exceeds medications; depression: CBT + med superior to either alone. Assess suicide risk periodically, especially if new worsening. Safety plan for at-risk patients.

When to Seek Urgent Care

  • →Thoughts of suicide or self-harm — call 988 (Suicide & Crisis Lifeline)
  • →Inability to care for yourself or your dependents
  • →Panic attacks that are frequent or disabling
  • →Symptoms worsening despite treatment

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Individual treatment plans vary. Always consult your healthcare provider before starting, stopping, or changing any medication or treatment.

Managing Mental Health?

Book a telehealth visit with Pineapple Primary Care to get a personalized depression & anxiety management plan.

Book an Appointment

Quick Facts

  • ✓PHQ-9 score below 5 (remission) from baseline
  • ✓Restored ability to work, socialize, and function daily
  • ✓Improved sleep quality
← Back to Chronic Disease Management